Open source so hope iys ok11 Mar 2025 19:59
Grok’s generated final investment analysis for SkinBioTherapeutics (SBTX), OptiBiotix Health (OPTI), and ProBiotix Health (PBX) over the 2025–2030 horizon, incorporating the new commercial partnership details you provided, alongside the FY 2025 revenue forecasts, key drivers, financial stability, and all prior inputs (e.g., Matrixyl’s £400M sales, SBTX’s 10% lysate royalty, regulatory trends favoring natural lysates). I’ve expanded on the partnerships’ potential to improve the analysis, assessing their impact on growth as of March 9, 2025, with SBTX’s SkinBiotix lysate launching in April 2025. https://lemminginvestor.substack.com/p/investor-podcast-16